Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alt801
2. Glxc-26955
3. 2538014-94-5
| Molecular Weight | 3790 g/mol |
|---|---|
| Molecular Formula | C178H270N38O53 |
| XLogP3 | -7.4 |
| Hydrogen Bond Donor Count | 51 |
| Hydrogen Bond Acceptor Count | 57 |
| Rotatable Bond Count | 131 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 1500 |
| Heavy Atom Count | 269 |
| Formal Charge | 0 |
| Complexity | 8720 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 34 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Pemvidutide is a Peptide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Liver Diseases, Alcoholic.
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2025
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pemvidutide Safety and Efficacy In Alcohol-Associated Liver Disease
Details : Pemvidutide is a Peptide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Liver Diseases, Alcoholic.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 08, 2025
Details:
Pemvidutide is a Peptide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Alcoholism.
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2025
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pemvidutide Safety and Efficacy In AUD Patients with Obesity/Overweight
Details : Pemvidutide is a Peptide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Alcoholism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 23, 2025
Details:
The Company’s lead program is ALT-801 (pemvidutide), a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD).
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 19, 2025
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altimmune Starts Phase 2 RECLAIM Trial of Pemvidutide in Alcohol Use Disorder
Details : The Company’s lead program is ALT-801 (pemvidutide), a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD).
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 19, 2025
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2024
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altimmune Completes End-Of-Phase 2 Meeting with FDA for Pemvidutide
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 07, 2024
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide for MASH
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 30, 2024
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2024
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altimmune Weight Loss Drug Shows Reduced Muscle Loss in Trials
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 28, 2024
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2023
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 29, 2023
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2023
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 26, 2023
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 12, 2023
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 12, 2023
Details:
Pemvidutide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Lead Product(s): Pemvidutide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 14, 2023
Lead Product(s) : Pemvidutide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pemvidutide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
92
PharmaCompass offers a list of Pemvidutide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pemvidutide manufacturer or Pemvidutide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pemvidutide manufacturer or Pemvidutide supplier.
PharmaCompass also assists you with knowing the Pemvidutide API Price utilized in the formulation of products. Pemvidutide API Price is not always fixed or binding as the Pemvidutide Price is obtained through a variety of data sources. The Pemvidutide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pemvidutide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pemvidutide, including repackagers and relabelers. The FDA regulates Pemvidutide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pemvidutide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Pemvidutide supplier is an individual or a company that provides Pemvidutide active pharmaceutical ingredient (API) or Pemvidutide finished formulations upon request. The Pemvidutide suppliers may include Pemvidutide API manufacturers, exporters, distributors and traders.
Pemvidutide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pemvidutide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pemvidutide GMP manufacturer or Pemvidutide GMP API supplier for your needs.
A Pemvidutide CoA (Certificate of Analysis) is a formal document that attests to Pemvidutide's compliance with Pemvidutide specifications and serves as a tool for batch-level quality control.
Pemvidutide CoA mostly includes findings from lab analyses of a specific batch. For each Pemvidutide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pemvidutide may be tested according to a variety of international standards, such as European Pharmacopoeia (Pemvidutide EP), Pemvidutide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pemvidutide USP).
